Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells

Oncogene

Volumn 32, Issue 19, 2013, Pages 2390-2402

  Cotrim, C Z ^a   Fabris, V ^b   Doria, M L ^a   Lindberg, K ^c   Gustafsson, J A ^c,d   Amado, F ^a   Lanari, C ^b   Helguero, L A ^a  

^a UNIVERSITY OF AVEIRO   (Portugal)

^b Intituto de Biologia y Medicina Experimental   (Argentina)

^c KAROLINSKA INSTITUTE   (Sweden)

^d University of Houston   (United States)

Author keywords

apoptosis; breast cancer; ERK 1 2; estrogen receptor beta; mammary gland; proliferation

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; BREAST CANCER; BREAST EPITHELIUM; BREAST HYPERPLASIA; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; UPREGULATION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; EPITHELIAL CELLS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 84877604335     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.261     Document Type: Article

References (50)

1. Liu Y, Gao H, Marstrand TT, Strom A, Valen E, Sandelin A et al. The genome landscape of ERalpha-and ERbeta-binding DNA regions. Proc Natl Acad Sci USA 2008; 105: 2604-2609.
2. Grober OM, Mutarelli M, Giurato G, Ravo M, Cicatiello L, De Filippo MR et al. Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics 2011; 12: 36.
3. Ciarloni L, Mallepell S, Brisken C. Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci USA 2007; 104: 5455-5460.
4. Forster C, Makela S, Warri A, Kietz S, Becker D, Hultenby K et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci USA 2002; 99: 15578-15583.
5. Helguero LA, Faulds MH, Gustafsson JA, Haldosen LA. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005; 24: 6605-6616.
6. Helguero LA, Lindberg K, Gardmo C, Schwend T, Gustafsson JA, Haldosen LA. Different roles of estrogen receptors alpha and beta in the regulation of E-cadherin protein levels in a mouse mammary epithelial cell line. Cancer Res 2008; 68: 8695-8704.
7. Su Y, Simmen RC. Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates beta-catenin signaling in mammary epithelial cells. Carcinogenesis 2009; 30: 331-339.
8. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-643.
9. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 2002; 277: 24353-24360.
10. Matthews J, Wihlen B, Tujague M, Wan J, Strom A, Gustafsson JA. Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 2006; 20: 534-543.
11. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001; 142: 4120-4130.
12. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004; 101: 1566-1571.
13. Lindberg K, Strom A, Lock JG, Gustafsson JA, Haldosen LA, Helguero LA. Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells. J Cell Physiol 2010; 222: 156-167.
14. Lindberg K, Helguero LA, Omoto Y, Gustafsson JA, Haldosen LA. Estrogen receptor beta represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res 2011; 13: R43.
15. Wu X, Subramaniam M, Grygo SB, Sun Z, Negron V, Lingle WL et al. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res 2011; 13: R27.
16. Green CA, Peter MB, Speirs V, Shaaban AM. The potential role of ER beta isoforms in the clinical management of breast cancer. Histopathology 2008; 53: 374-380.
17. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001; 61: 2537-2541.
18. Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 2003; 201: 213-220.
19. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000; 156: 29-35.
20. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008; 26: 3727-3734.
21. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008; 14: 5228-5235.
22. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 2006; 95: 616-626.
23. Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 2001; 98: 15197-15202.
24. Sanchez M, Picard N, Sauve K, Tremblay A. Challenging estrogen receptor beta with phosphorylation. Trends Endocrinol Metab 2010; 21: 104-110.
25. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 2006; 20: 3120-3132.
26. Soldati R, Wargon V, Cerliani JP, Giulianelli S, Vanzulli SI, Gorostiaga MA et al. Inhibition of mammary tumor growth by estrogens: is there a specific role for estrogen receptors alpha and beta? Breast Cancer Res Treat 2010; 123: 709-724.
27. Rahal OM, Simmen RC. Paracrine-acting adiponectin promotes mammary epithelial differentiation and synergizes with genistein to enhance transcriptional response to estrogen receptor {beta} signaling. Endocrinology 2011; 152: 3409-3421.
28. Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA et al. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 2001; 61: 293-302.
29. Merlo GR, Venesio T, Taverna D, Marte BM, Callahan R, Hynes NE. Growth suppression of normal mammary epithelial cells by wild-type p53. Oncogene 1994; 9: 443-453.
30. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 1995; 9: 2170-2183.
31. Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 2005; 17: 631-636.
32. Aliaga A, Rousseau JA, Ouellette R, Cadorette J, van Lier JE, Lecomte R et al. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nucl Med Biol 2004; 31: 761-770.
33. Frasor J, Barnett DH, Danes JM, Hess R, Parlow AF, Katzenellenbogen BS. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. Endocrinology 2003; 144: 3159-3166.
34. Novaro V, Roskelley CD, Bissell MJ. Collagen-IV and laminin-1 regulate estrogen receptor alpha expression and function in mouse mammary epithelial cells. J Cell Sci 2003; 116: 2975-2986.
35. Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLachlan JA. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 1993; 7: 992-998.
36. Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, De Falco A et al. Crosstalk between EGFR and extranuclear steroid receptors. Ann N Y Acad Sci 2006; 1089: 194-200.
37. Williams C, Edvardsson K, Lewandowski SA, Strom A, Gustafsson JA. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 2008; 27: 1019-1032.
38. Merlo GR, Basolo F, Fiore L, Duboc L, Hynes NE. p53-dependent and p53-inde-pendent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. J Cell Biol 1995; 128: 1185-1196.
39. Merlo GR, Graus-Porta D, Cella N, Marte BM, Taverna D, Hynes NE. Growth differentiation and survival of HC11 mammary epithelial cells: diverse effects of receptor tyrosine kinase-activating peptide growth factors. Eur J Cell Biol 1996; 70: 97-105.
40. Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L. Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr Rev 2011; 32: 597-622.
41. Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W et al. Soy food intake and breast cancer survival. JAMA 2009; 302: 2437-2443.
42. Nilsson S, Gustafsson JA. Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Ther 2011; 89: 44-55.
43. Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R et al. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 2008; 10: R74.
44. Matthews J, Gustafsson JA. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 2003; 3: 281-292.
45. Cotroneo MS, Wang J, Fritz WA, Eltoum IE, Lamartiniere CA. Genistein action in the prepubertal mammary gland in a chemoprevention model. Carcinogenesis 2002; 23: 1467-1474.
46. Walker VR, Korach KS. Estrogen receptor knockout mice as a model for endocrine research. ILAR J 2004; 45: 455-461.
47. Hamilton-Burke W, Coleman L, Cummings M, Green CA, Holliday DL, Horgan K et al. Phosphorylation of estrogen receptor beta at serine 105 is associated with good prognosis in breast cancer. Am J Pathol 2010; 177: 1079-1086.
48. Ball RK, Friis RR, Schoenenberger CA, Doppler W, Groner B. Prolactin regulation of beta-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line. EMBO J 1988; 7: 2089-2095.
49. Reichmann E, Schwarz H, Deiner EM, Leitner I, Eilers M, Berger J et al. Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion. Cell 1992; 71: 1103-1116.
50. Weitsman GE, Skliris G, Ung K, Peng B, Younes M, Watson PH, Murphy LC. Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res Treat 2006; 100: 23-31.